Penumbra, Inc. (PEN)

Penumbra's stock has experienced significant momentum, with increases of approximately 11% over one week, 14% over one month, and 41% over three months as of mid-January 2026. In Q3 CY2025, Penumbra beat revenue expectations with sales up 17.8% year-on-year to $354.7 million. The company's non-GAAP profit of $0.97 per share was also 5.3% above analysts' consensus estimates. A share buyback program was authorized on August 13, 2024, permitting the company to repurchase up to $200,000,000 in shares.

The provided search results do not contain explicit information detailing the demand seasonality for Penumbra, Inc.'s products and services. Demand can be influenced by factors beyond typical seasonal patterns, such as technological advancements and new product introductions. The recurring need for Penumbra's medical devices, coupled with growing global demand for advanced treatments, generally provides stability and opportunities for long-term growth in the medical device industry.

Penumbra, Inc. is a global healthcare company focused on designing, developing, manufacturing, and marketing innovative medical devices. Operating in the Medical Devices industry, Penumbra aims to improve patient lives through differentiated products with clinical advantages, primarily in neuro and vascular interventional markets. The company's product portfolio includes thrombectomy products, embolization and access products, and immersive healthcare solutions, featuring the REAL Immersive System for rehabilitation and mental well-being.

Penumbra, Inc. operates in the United States and internationally, with 76.8% of its revenue from the U.S. and 23.2% from international markets. The company sells directly to healthcare providers in the United States, most of Europe, Canada, and Australia, while utilizing distributors in other international markets. Penumbra is strategically investing in global expansion, including a new manufacturing facility in Costa Rica. International revenue growth has decreased due to headwinds in China, expected to ease in the second half of 2025.

Penumbra's brand reputation is positive, driven by its innovative approach and strong financial performance. The company is recognized for its pioneering spirit and ability to translate scientific advancements into tangible patient benefits. Penumbra has maintained its position as a leading thrombectomy company due to its innovative approach to stroke and vascular care. Key events contributing to its reputation include strong financial performance, an innovative product portfolio, expansion into immersive healthcare, and analyst sentiment.

Penumbra, Inc. has a diverse ownership structure, with institutional investors holding approximately 62.58% of the company's stock, insiders owning about 3.06%, and public companies and individual investors holding 34.36%. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Notable individual insiders who own company stock include Adam Elsesser, Arani Bose, and Johanna Roberts. In the past three months, Penumbra insiders have sold more company stock than they have bought, with sales totaling over $10 million.